{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:40:34Z","timestamp":1793040034695,"version":"4.5.0"},"reference-count":123,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T00:00:00Z","timestamp":1674691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Canadian Institutes of Health Research (CIHR)"},{"name":"Natural Sciences and Engineering Research Council (NSERC)"},{"name":"Fonds de Recherche du Qu\u00e9bec Nature et Technologies (FRQNT)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>In the 1990s, adenovirus became one of the first virus types to be genetically engineered to selectively destroy cancer cells. In the intervening years, the field of \u201concolytic viruses\u201d has slowly progressed and culminated in 2015 with the FDA approval of Talimogene laherparepvec, a genetically engineered herpesvirus, for the treatment of metastatic melanoma. Despite the slower progress in translating oncolytic adenovirus to the clinic, interest in the virus remains strong. Among all the clinical trials currently using viral oncolytic agents, the largest proportion of these are using recombinant adenovirus. Many trials are currently underway to use oncolytic virus in combination with immune checkpoint inhibitors (ICIs), and early results using oncolytic adenovirus in this manner are starting to show promise. Many of the existing strategies to engineer adenoviruses were designed to enhance selective tumor cell replication without much regard to interactions with the immune system. Adenovirus possesses a wide range of viral factors to attenuate both innate anti-viral pathways and immune cell killing. In this review, we summarize the strategies of oncolytic adenoviruses currently in clinical trials, and speculate how the mutational backgrounds of these viruses may impact upon the efficacy of these agents in oncolytic and immunotherapy. Despite decades of research on human adenoviruses, the interactions that these viruses have with the immune system remains one of the most understudied aspects of the virus and needs to be improved to rationally design the next generation of engineered viruses.<\/jats:p>","DOI":"10.3390\/v15020358","type":"journal-article","created":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T01:58:59Z","timestamp":1674784739000},"page":"358","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["A Renaissance for Oncolytic Adenoviruses?"],"prefix":"10.3390","volume":"15","author":[{"given":"Paola","family":"Blanchette","sequence":"first","affiliation":[{"name":"Goodman Cancer Institute, McGill University, Montr\u00e9al, QC H3A 1A3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3713-6839","authenticated-orcid":false,"given":"Jose G.","family":"Teodoro","sequence":"additional","affiliation":[{"name":"Goodman Cancer Institute, McGill University, Montr\u00e9al, QC H3A 1A3, Canada"},{"name":"Department of Biochemistry, McGill University, Montr\u00e9al, QC H3G 1Y6, Canada"},{"name":"Department of Microbiology and Immunology, McGill University, Montr\u00e9al, QC H3G 1Y6, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1126\/science.1851332","article-title":"Experimental therapy of human glioma by means of a genetically engineered virus mutant","volume":"252","author":"Martuza","year":"1991","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41568-018-0009-4","article-title":"Oncolytic viruses as engineering platforms for combination immunotherapy","volume":"18","author":"Pettigrew","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/jnci\/djj111","article-title":"China Approves World\u2019s First Oncolytic Virus Therapy For Cancer Treatment","volume":"98","author":"Garber","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.274.5286.373","article-title":"An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells","volume":"274","author":"Bischoff","year":"1996","journal-title":"Science"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ccr.2004.11.012","article-title":"Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity","volume":"6","author":"Johnson","year":"2004","journal-title":"Cancer Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.vaccine.2009.10.145","article-title":"International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials","volume":"28","author":"Mast","year":"2010","journal-title":"Vaccine"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1200\/JCO.2022.40.16_suppl.4597","article-title":"CORE1: Phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG)","volume":"40","author":"Li","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3892\/ijo.2015.3045","article-title":"The antitumor effects of oncolytic adenovirus H101 against lung cancer","volume":"47","author":"Lei","year":"2015","journal-title":"Int. J. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1073\/pnas.91.8.3054","article-title":"Gene therapy for brain tumors: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo","volume":"91","author":"Chen","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Zheng, H., Dai, W., Antonia, S., Cantwell, M.J., and Beg, A.A. (2022, November 20). Abstract 4578: Development of MEM-288, a Dual-Transgene Armed and Conditionally Replication-Enhanced Oncolytic Adenovirus with Potent Systemic Antitumor Immunity. Available online: https:\/\/aacrjournals.org\/cancerres\/article\/80\/16_Supplement\/4578\/643321\/Abstract-4578-Development-of-MEM-288-a-dual.","DOI":"10.1158\/1538-7445.AM2020-4578"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5846","DOI":"10.1158\/1078-0432.CCR-17-0285","article-title":"Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus","volume":"23","author":"Eriksson","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/gt.2016.80","article-title":"Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment","volume":"24","author":"Eriksson","year":"2017","journal-title":"Gene Ther"},{"key":"ref_13","first-page":"S206","article-title":"516. A Novel Oncolytic Adenovirus Expressing Tumor Microenvironment Stimulators to Evoke and Facilitate Anti-Tumor Immune Responses","volume":"24 (Suppl. 1)","author":"Wenthe","year":"2016","journal-title":"Cancer-Oncolytic DNA Viruses"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1016\/j.juro.2012.07.097","article-title":"A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer","volume":"188","author":"Burke","year":"2012","journal-title":"J. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/cgt.2011.41","article-title":"Deletion analysis of Ad5 E1a transcriptional control region: Impact on tumor-selective expression of E1a and E1b","volume":"18","author":"Hedjran","year":"2011","journal-title":"Cancer Gene Ther."},{"key":"ref_16","first-page":"5184","article-title":"Toxicology and biodistribution of AdAPT-001, a replication-competent type 5 adenovirus with a trap for the immunosuppressive cytokine, TGF-beta","volume":"11","author":"Larson","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1158\/1078-0432.CCR-1075-3","article-title":"Telomerase-specific replication-selective virotherapy for human cancer","volume":"10","author":"Kawashima","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.ejca.2011.12.020","article-title":"A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression","volume":"48","author":"Yamasaki","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Kuhn, I., Harden, P., Bauzon, M., Chartier, C., Nye, J., Thorne, S., Reid, T., Ni, S., Lieber, A., and Fisher, K. (2008). Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS ONE, 3.","DOI":"10.1371\/journal.pone.0002409"},{"key":"ref_20","unstructured":"Amiji, M.M., and Scheherazade Milane, L. (2022). Cancer Immunology and Immunotherapy, Academic Press."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1525-0016(03)00200-4","article-title":"Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus","volume":"8","author":"Kanerva","year":"2003","journal-title":"Mol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/mt.2010.161","article-title":"Treatment of cancer patients with a serotype 5\/3 chimeric oncolytic adenovirus expressing GMCSF","volume":"18","author":"Koski","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/ijc.29048","article-title":"Oncolytic adenovirus and doxorubicin-based chemotherapy results in synergistic antitumor activity against soft-tissue sarcoma","volume":"136","author":"Siurala","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Havunen, R., Kalliokoski, R., Siurala, M., Sorsa, S., Santos, J.M., Cervera-Carrascon, V., Anttila, M., and Hemminki, A. (2021). Cytokine-Coding Oncolytic Adenovirus TILT-123 Is Safe, Selective, and Effective as a Single Agent and in Combination with Immune Checkpoint Inhibitor Anti-PD-1. Cells, 10.","DOI":"10.3390\/cells10020246"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.vaccine.2018.02.070","article-title":"Preclinical development of peptide vaccination combined with oncolytic MG1-E6E7 for HPV-associated cancer","volume":"36","author":"Atherton","year":"2018","journal-title":"Vaccine"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e14637","DOI":"10.1200\/JCO.2017.35.15_suppl.e14637","article-title":"Phase I study of oncolytic virus (OV) MG1 maraba\/MAGE-A3 (MG1MA3), with and without transgenic MAGE-A3 adenovirus vaccine (AdMA3) in incurable advanced\/metastatic MAGE-A3-expressing solid tumours: CCTG IND.214","volume":"35","author":"Jonker","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.omto.2021.05.009","article-title":"Hyaluronidase expression within tumors increases virotherapy efficacy and T cell accumulation","volume":"22","author":"Moreno","year":"2021","journal-title":"Mol. Ther. Oncolytics."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/hum.2007.002","article-title":"Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma","volume":"18","author":"Ulasov","year":"2007","journal-title":"Hum. Gene Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1089\/hum.2013.229","article-title":"ORCA-010, a novel potency-enhanced oncolytic adenovirus, exerts strong antitumor activity in preclinical models","volume":"25","author":"Dong","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Klawitter, M., El-Ayoubi, A., Buch, J., R\u00fcttinger, J., Ehrenfeld, M., Lichtenegger, E., Kr\u00fcger, M.A., Mantwill, K., Koll, F.J., and Kowarik, M.C. (2022). The Oncolytic Adenovirus XVir-N-31, in Combination with the Blockade of the PD-1\/PD-L1 Axis, Conveys Abscopal Effects in a Humanized Glioblastoma Mouse Model. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23179965"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s00432-022-03931-4","article-title":"Reversing resistance to immune checkpoint inhibitor by adding recombinant human adenovirus type 5 in a patient with small cell lung cancer with promoted immune infiltration: A case report","volume":"148","author":"Zhao","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1002\/cam4.4845","article-title":"Oncolytic adenovirus H101 ameliorate the efficacy of anti-PD -1 monotherapy in colorectal cancer","volume":"11","author":"Huang","year":"2022","journal-title":"Cancer Med."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Heini\u00f6, C., Clubb, J., Kudling, T., Quixabeira, D., Cervera-Carrascon, V., Havunen, R., Gr\u00f6nberg-V\u00e4h\u00e4-Koskela, S., Santos, J.M., Tapper, J., and Kanerva, A. (2022). Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers. Diseases, 10.","DOI":"10.3390\/diseases10030052"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"794251","DOI":"10.3389\/fimmu.2022.794251","article-title":"Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer","volume":"13","author":"Clubb","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2028960","DOI":"10.1080\/2162402X.2022.2028960","article-title":"Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1","volume":"11","author":"Quixabeira","year":"2022","journal-title":"Oncoimmunology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1038\/s41417-021-00389-3","article-title":"Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model","volume":"29","author":"Zhang","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e000763","DOI":"10.1136\/jitc-2020-000763","article-title":"Relaxin-expressing oncolytic adenovirus induces remodeling of physical and immunological aspects of cold tumor to potentiate PD-1 blockade","volume":"8","author":"Jung","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1093\/nar\/19.16.4387","article-title":"Inhibition of the cellular response to interferons by products of the adenovirus type 5 E1A oncogene","volume":"19","author":"Ackrill","year":"1991","journal-title":"Nucleic Acids Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"7913","DOI":"10.1073\/pnas.88.18.7913","article-title":"Repression of the interferon signal transduction pathway by the adenovirus E1A oncogene","volume":"88","author":"Gutch","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"7459","DOI":"10.1073\/pnas.88.17.7459","article-title":"Inhibition of interferon-inducible gene expression by adenovirus E1A proteins: Block in transcriptional complex formation","volume":"88","author":"Kalvakolanu","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1128\/JVI.80.3.1376-1384.2006","article-title":"Adenovirus Virus-Associated RNA Is Processed to Functional Interfering RNAs Involved in Virus Production","volume":"80","author":"Aparicio","year":"2006","journal-title":"J. Virol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0092-8674(86)90383-1","article-title":"Adenovirus VAI RNA antagonizes the antiviral action of interferon by preventing activation of the interferon-induced eIF-2\u03b1 kinase","volume":"45","author":"Kitajewski","year":"1986","journal-title":"Cell"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0092-8674(86)90460-5","article-title":"A mechanism for the control of protein synthesis by adenovirus VA RNAI","volume":"44","author":"Mariano","year":"1986","journal-title":"Cell"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/sj.onc.1203251","article-title":"A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo","volume":"19","author":"Fueyo","year":"2000","journal-title":"Oncogene"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s13277-013-1149-5","article-title":"Combination of E2F-1 promoter-regulated oncolytic adenovirus and cytokine-induced killer cells enhances the antitumor effects in an orthotopic rectal cancer model","volume":"35","author":"Yan","year":"2014","journal-title":"Tumor Biol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Fonseca, G.J., Cohen, M.J., Nichols, A.C., Barrett, J.W., and Mymryk, J.S. (2013). Viral Retasking of hBre1\/RNF20 to Recruit hPaf1 for Transcriptional Activation. PLoS Pathog., 9.","DOI":"10.1371\/journal.ppat.1003411"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.chom.2012.05.005","article-title":"Adenovirus Evasion of Interferon-Mediated Innate Immunity by Direct Antagonism of a Cellular Histone Posttranslational Modification","volume":"11","author":"Fonseca","year":"2012","journal-title":"Cell Host Microbe"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.virol.2011.09.025","article-title":"Adenovirus E1A interacts directly with, and regulates the level of expression of, the immunoproteasome component MECL1","volume":"421","author":"Berhane","year":"2011","journal-title":"Virology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.chom.2017.11.008","article-title":"The Adenovirus E1A C Terminus Suppresses a Delayed Antiviral Response and Modulates RAS Signaling","volume":"22","author":"Zemke","year":"2017","journal-title":"Cell Host Microbe"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1002\/1873-3468.13694","article-title":"The biology of the adenovirus E1B 55K protein","volume":"593","author":"Hidalgo","year":"2019","journal-title":"FEBS Lett."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1128\/JVI.75.12.5443-5447.2001","article-title":"Does the Antitumor Adenovirus ONYX-015\/dl1520 Selectively Target Cells Defective in the p53 Pathway?","volume":"75","author":"Dix","year":"2001","journal-title":"J. Virol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"S157","DOI":"10.4161\/cbt.216","article-title":"Cancer-specific viruses and the development of ONYX-015","volume":"2","author":"McCormick","year":"2003","journal-title":"Cancer Biol. Ther."},{"key":"ref_54","first-page":"241","article-title":"Pathways used by adenovirus E1B 19K to inhibit apoptosis","volume":"52","author":"Degenhardt","year":"2000","journal-title":"Symp. Soc. Exp. Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1128\/jvi.52.2.410-419.1984","article-title":"Mutations in the gene encoding the adenovirus early region 1B 19,000-molecular-weight tumor antigen cause the degradation of chromosomal DNA","volume":"52","author":"White","year":"1984","journal-title":"J. Virol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1128\/JVI.02372-13","article-title":"Adenovirus E1B 19-Kilodalton Protein Modulates Innate Immunity through Apoptotic Mimicry","volume":"88","author":"Radke","year":"2014","journal-title":"J. Virol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1126\/science.275.5304.1320","article-title":"Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5","volume":"275","author":"Bergelson","year":"1997","journal-title":"Science"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0092-8674(93)90231-E","article-title":"Integrins \u03b1v\u03b23 and \u03b1v\u03b25 promote adenovirus internalization but not virus attachment","volume":"73","author":"Wickham","year":"1993","journal-title":"Cell"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1634\/stemcells.18-3-176","article-title":"Maturation and Lineage-Specific Expression of the Coxsackie and Adenovirus Receptor in Hematopoietic Cells","volume":"18","author":"Rebel","year":"2000","journal-title":"STEM CELLS"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/sj.cgt.7700947","article-title":"Expression of the coxsackievirus- and adenovirus receptor in gastrointestinal cancer correlates with tumor differentiation","volume":"13","author":"Korn","year":"2006","journal-title":"Cancer Gene Ther."},{"key":"ref_61","first-page":"6592","article-title":"The mechanism of the growth-inhibitory effect of coxsackie and adenovirus receptor (CAR) on human bladder cancer: A functional analysis of car protein structure","volume":"61","author":"Okegawa","year":"2001","journal-title":"Cancer Res."},{"key":"ref_62","first-page":"3812","article-title":"Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: Potential relevance to gene therapy","volume":"62","author":"Sudilovsky","year":"2002","journal-title":"Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/bjc.2013.509","article-title":"Presence of the Coxsackievirus and Adenovirus Receptor (CAR) in human neoplasms: A multitumour array analysis","volume":"109","author":"Reeh","year":"2013","journal-title":"Br. J. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/bjc.2011.116","article-title":"Impact of the coxsackievirus and adenovirus receptor on the adenoma\u2013carcinoma sequence of colon cancer","volume":"104","author":"Stecker","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"925","DOI":"10.4161\/cc.7.7.5621","article-title":"Proteasome inhibitor MG-132 modifies coxsackie and adenovirus receptor expression in colon cancer cell line lovo","volume":"7","author":"Zhang","year":"2008","journal-title":"Cell Cycle"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/nsmb1190","article-title":"Adenovirus type 11 binding alters the conformation of its receptor CD46","volume":"14","author":"Persson","year":"2007","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"9183","DOI":"10.1128\/JVI.77.17.9183-9191.2003","article-title":"Adenovirus Type 11 Uses CD46 as a Cellular Receptor","volume":"77","author":"Segerman","year":"2003","journal-title":"J. Virol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1128\/JVI.06181-11","article-title":"Avidity Binding of Human Adenovirus Serotypes 3 and 7 to the Membrane Cofactor CD46 Triggers Infection","volume":"86","author":"Trinh","year":"2012","journal-title":"J. Virol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nm.2270","article-title":"Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14","volume":"17","author":"Wang","year":"2010","journal-title":"Nat. Med."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Elvington, M., Liszewski, M.K., and Atkinson, J.P. (2021). CD46 and Oncologic Interactions: Friendly Fire against Cancer. Antibodies, 9.","DOI":"10.3390\/antib9040059"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1586\/era.09.47","article-title":"Predictive modeling in cancer: Where systems biology meets the stock market","volume":"9","author":"Abbod","year":"2009","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/path.1821","article-title":"Desmoglein 2 is expressed abnormally rather than mutated in familial and sporadic gastric cancer","volume":"207","author":"Biedermann","year":"2005","journal-title":"J. Pathol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2340\/0001555576417420","article-title":"Abnormal desmoglein expression by squamous cell carcinoma cells","volume":"76","author":"Harada","year":"1996","journal-title":"Acta Derm. Venereol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1046\/j.1365-2249.2001.01458.x","article-title":"Membrane cofactor protein (MCP; CD46) expression in transgenic mice","volume":"124","author":"Kemper","year":"2001","journal-title":"Clin. Exp. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1038\/sj.jid.5700849","article-title":"Homo- and Heterotypic Cell Contacts in Malignant Melanoma Cells and Desmoglein 2 as a Novel Solitary Surface Glycoprotein","volume":"127","author":"Schmitt","year":"2007","journal-title":"J. Investig. Dermatol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"910","DOI":"10.5858\/arpa.2013-0064-OA","article-title":"Systematic Immunohistochemical Analysis of the Expression of CD46, CD55, and CD59 in Colon Cancer","volume":"138","author":"Shang","year":"2014","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_77","first-page":"4943","article-title":"CD46 expression is indicative of shorter revival-free survival for ovarian cancer patients","volume":"26","author":"Surowiak","year":"2007","journal-title":"Anticancer. Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1699-0463.1998.tb00233.x","article-title":"The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues","volume":"106","author":"Thorsteinsson","year":"1998","journal-title":"Apmis"},{"key":"ref_79","first-page":"183","article-title":"Identification of metastasis-associated genes in prostate cancer by genetic profiling of human prostate cancer cell lines","volume":"25","author":"Trojan","year":"2005","journal-title":"Anticancer. Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/jgm.543","article-title":"Development of an adenoviral vector system with adenovirus serotype 35 tropism; efficient transient gene transfer into primary malignant hematopoietic cells","volume":"6","author":"Nilsson","year":"2004","journal-title":"J. Gene Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/sj.cgt.7700599","article-title":"An adenoviral vector containing an arg\u2013gly\u2013asp (RGD) motif in the fiber knob enhances protein product levels from transgenes refractory to expression","volume":"10","author":"Campbell","year":"2003","journal-title":"Cancer Gene Ther."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"9706","DOI":"10.1128\/JVI.72.12.9706-9713.1998","article-title":"An Adenovirus Vector with Genetically Modified Fibers Demonstrates Expanded Tropism via Utilization of a Coxsackievirus and Adenovirus Receptor-Independent Cell Entry Mechanism","volume":"72","author":"Dmitriev","year":"1998","journal-title":"J. Virol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1089\/10430340260201734","article-title":"Double Modification of Adenovirus Fiber with RGD and Polylysine Motifs Improves Coxsackievirus\u2013Adenovirus Receptor-Independent Gene Transfer Efficiency","volume":"13","author":"Wu","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1128\/jvi.12.3.643-652.1973","article-title":"Use of Nondefective Adenovirus-Simian Virus 40 Hybrids for Mapping the Simian Virus 40 Genome","volume":"12","author":"Kelly","year":"1973","journal-title":"J. Virol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0092-8674(78)90148-4","article-title":"Isolation of deletion and substitution mutants of adenovirus type 5","volume":"13","author":"Jones","year":"1978","journal-title":"Cell"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/08830180490265556","article-title":"Functions and Mechanisms of Action of the Adenovirus E3 Proteins","volume":"23","author":"Lichtenstein","year":"2004","journal-title":"Int. Rev. Immunol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1074\/jbc.M008218200","article-title":"Three Adenovirus E3 Proteins Cooperate to Evade Apoptosis by Tumor Necrosis Factor-related Apoptosis-inducing Ligand Receptor-1 and -2","volume":"276","author":"Benedict","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"10072","DOI":"10.1073\/pnas.95.17.10072","article-title":"The adenovirus E3\/10.4K\u201314.5K proteins down-modulate the apoptosis receptor Fas\/Apo-1 by inducing its internalization","volume":"95","author":"Elsing","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"9716","DOI":"10.1128\/JVI.76.19.9716-9723.2002","article-title":"The Adenovirus E3 RID Complex Protects Some Cultured Human T and B Lymphocytes from Fas-Induced Apoptosis","volume":"76","author":"McNees","year":"2002","journal-title":"J. Virol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"8299","DOI":"10.1128\/jvi.71.11.8299-8306.1997","article-title":"The adenovirus E3-10.4K\/14.5K complex mediates loss of cell surface Fas (CD95) and resistance to Fas-induced apoptosis","volume":"71","author":"Shisler","year":"1997","journal-title":"J. Virol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/33712","article-title":"Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells","volume":"392","author":"Tollefson","year":"1998","journal-title":"Nature"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"8875","DOI":"10.1128\/JVI.75.19.8875-8887.2001","article-title":"Inhibition of TRAIL-Induced Apoptosis and Forced Internalization of TRAIL Receptor 1 by Adenovirus Proteins","volume":"75","author":"Tollefson","year":"2001","journal-title":"J. Virol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1128\/jvi.65.6.3083-3094.1991","article-title":"The E1B 19,000-molecular-weight protein of group C adenoviruses prevents tumor necrosis factor cytolysis of human cells but not of mouse cells","volume":"65","author":"Gooding","year":"1991","journal-title":"J. Virol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.1128\/jvi.70.8.4904-4913.1996","article-title":"The adenovirus E3-14.7K protein and the E3-10.4K\/14.5K complex of proteins, which independently inhibit tumor necrosis factor (TNF)-induced apoptosis, also independently inhibit TNF-induced release of arachidonic acid","volume":"70","author":"Krajcsi","year":"1996","journal-title":"J. Virol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0952-7915(99)80064-8","article-title":"Immune responses to adenoviruses: Viral evasion mechanisms and their implications for the clinic","volume":"11","author":"Wold","year":"1999","journal-title":"Curr. Opin. Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1128\/JVI.76.4.1578-1587.2002","article-title":"Adenovirus E3-6.7K Maintains Calcium Homeostasis and Prevents Apoptosis and Arachidonic Acid Release","volume":"76","author":"Moise","year":"2002","journal-title":"J. Virol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"4114","DOI":"10.1128\/jvi.65.8.4114-4123.1991","article-title":"The 10,400- and 14,500-dalton proteins encoded by region E3 of adenovirus function together to protect many but not all mouse cell lines against lysis by tumor necrosis factor","volume":"65","author":"Gooding","year":"1991","journal-title":"J. Virol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.4049\/jimmunol.145.9.3080","article-title":"The adenovirus E3-14.7K protein is a general inhibitor of tumor necrosis factor-mediated cytolysis","volume":"145","author":"Gooding","year":"1990","journal-title":"J. Immunol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"8502","DOI":"10.1128\/jvi.70.12.8502-8507.1996","article-title":"The activity of cytosolic phospholipase A2 is required for the lysis of adenovirus-infected cells by tumor necrosis factor","volume":"70","author":"Thorne","year":"1996","journal-title":"J. Virol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.4049\/jimmunol.138.11.3960","article-title":"Reduced allorecognition of adenovirus-2 infected cells","volume":"138","author":"Andersson","year":"1987","journal-title":"J. Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0092-8674(85)90026-1","article-title":"Impaired intracellular transport of class I MHC antigens as a possible means for adenoviruses to evade immune surveillance","volume":"43","author":"Andersson","year":"1985","journal-title":"Cell"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0092-8674(85)80079-9","article-title":"An adenovirus type 2 glycoprotein blocks cell surface expression of human histocompatibility class I antigens","volume":"41","author":"Burgert","year":"1985","journal-title":"Cell"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1073\/pnas.84.5.1356","article-title":"\u201cE3\/19K\u201d protein of adenovirus type 2 inhibits lysis of cytolytic T lymphocytes by blocking cell-surface expression of histocompatibility class I antigens","volume":"84","author":"Burgert","year":"1987","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1084\/jem.174.6.1629","article-title":"Retention of adenovirus E19 glycoprotein in the endoplasmic reticulum is essential to its ability to block antigen presentation","volume":"174","author":"Cox","year":"1991","journal-title":"J. Exp. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.4049\/jimmunol.143.6.2031","article-title":"Mouse anti-adenovirus cytotoxic T lymphocytes. Inhibition of lysis by E3 gp19K but not E3 14.7K","volume":"143","author":"Rawle","year":"1989","journal-title":"J. Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1002\/j.1460-2075.1990.tb07513.x","article-title":"Identification of a consensus motif for retention of transmembrane proteins in the endoplasmic reticulum","volume":"9","author":"Jackson","year":"1990","journal-title":"EMBO J."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1128\/jvi.70.4.2296-2306.1996","article-title":"The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells","volume":"70","author":"Tollefson","year":"1996","journal-title":"J. Virol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.omto.2021.03.002","article-title":"Cancer imaging and therapy utilizing a novel NIS-expressing adenovirus: The role of adenovirus death protein deletion","volume":"20","author":"Robertson","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1349-7006.2009.01407.x","article-title":"In Vivo bioimaging tracks conditionally replicative adenoviral replication and provides an early indication of viral antitumor efficacy","volume":"101","author":"Davydova","year":"2010","journal-title":"Cancer Sci."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1128\/jvi.65.11.5657-5662.1991","article-title":"Adenovirus virus-associated RNA and translation control","volume":"65","author":"Mathews","year":"1991","journal-title":"J. Virol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1073\/pnas.77.5.2424","article-title":"Structure of genes for virus-associated RNAI and RNAII of adenovirus type 2","volume":"77","author":"Mathews","year":"1980","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"5083","DOI":"10.1128\/jvi.70.8.5083-5099.1996","article-title":"Structure, function, and evolution of adenovirus-associated RNA: A phylogenetic approach","volume":"70","author":"Ma","year":"1996","journal-title":"J. Virol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"7377","DOI":"10.1093\/nar\/12.19.7377","article-title":"Adenovirus mutants with DNA sequence perturbations in the intragenic promoter of VAI RNA gene allow the enhanced transcription of VAII RNA gene in HeLa cells","volume":"12","author":"Bhat","year":"1984","journal-title":"Nucleic Acids Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1128\/jvi.60.2.363-368.1986","article-title":"Suppression of the translation defect phenotype specific for a virus-associated RNA-deficient adenovirus mutant in monkey cells by simian virus 40","volume":"60","author":"Subramanian","year":"1986","journal-title":"J. Virol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/0092-8674(82)90310-5","article-title":"Adenovirus VAI RNA is required for efficient translation of viral mRNAs at late times after infection","volume":"31","author":"Thimmappaya","year":"1982","journal-title":"Cell"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3390\/pharmaceutics3030338","article-title":"Adenovirus Vector-Derived VA-RNA-Mediated Innate Immune Responses","volume":"3","author":"Machitani","year":"2011","journal-title":"Pharmaceutics"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/jir.2006.26.1","article-title":"Induction of Interferon Synthesis by the PKR-Inhibitory VA RNAs of Adenoviruses","volume":"26","author":"Weber","year":"2006","journal-title":"J. Interf. Cytokine Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"17286","DOI":"10.1073\/pnas.1009823107","article-title":"Induction of type I interferon by adenovirus-encoded small RNAs","volume":"107","author":"Yamaguchi","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1017\/erm.2017.11","article-title":"Clinical and therapeutic potential of protein kinase PKR in cancer and metabolism","volume":"19","author":"Lopez","year":"2017","journal-title":"Expert Rev. Mol. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1038\/bcj.2013.42","article-title":"PKR negatively regulates leukemia progression in association with PP2A activation, Bcl-2 inhibition and increased apoptosis","volume":"3","author":"Cheng","year":"2013","journal-title":"Blood Cancer J."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1096\/fj.13-248294","article-title":"The impact of PKR activation: From neurodegeneration to cancer","volume":"28","author":"Marchal","year":"2014","journal-title":"FASEB J."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1440-1827.2005.01892.x","article-title":"Expression of double-stranded RNA-activated protein kinase in small-size peripheral adenocarcinoma of the lung","volume":"55","author":"Roh","year":"2005","journal-title":"Pathol. Int."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1034\/j.1600-0676.2000.020006450.x","article-title":"Protein expression of double-stranded RNA-activated protein kinase (PKR) in intrahepatic bile ducts in normal adult livers, fetal livers, primary biliary cirrhosis, hepatolithiasis and intrahepatic cholangiocarcinoma","volume":"20","author":"Terada","year":"2000","journal-title":"Liver"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/2\/358\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:16:32Z","timestamp":1760120192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/2\/358"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,26]]},"references-count":123,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["v15020358"],"URL":"https:\/\/doi.org\/10.3390\/v15020358","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,26]]}}}